These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 32274544

  • 1. [Combination therapy for metastatic hormone-sensitive prostate cancer: What? When? For whom?].
    Thomas C, Ohlmann CH.
    Urologe A; 2020 Jun; 59(6):665-672. PubMed ID: 32274544
    [Abstract] [Full Text] [Related]

  • 2. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
    Damodaran S, Lang JM, Jarrard DF.
    J Urol; 2019 May; 201(5):876-885. PubMed ID: 30747897
    [Abstract] [Full Text] [Related]

  • 3. [Apalutamide, Erleada®].
    Sautois B, Denis C.
    Rev Med Liege; 2022 Oct; 77(10):609-615. PubMed ID: 36226398
    [Abstract] [Full Text] [Related]

  • 4. [Treatment of metastatic, castration-resistant prostate cancer].
    von Amsberg G, Merseburger AS.
    Urologe A; 2020 Jun; 59(6):673-679. PubMed ID: 32274540
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Prostate Cancer Drug Therapy: What Have Clinicians Missed During the COVID-19 Pandemic.
    Rahnama'i MS.
    Am J Mens Health; 2022 Jun; 16(4):15579883221115593. PubMed ID: 35950609
    [Abstract] [Full Text] [Related]

  • 8. [Treatment situation in metastastic Castration Naive Prostate Cancer (mCRPC) and the implications on clinical routine].
    Wülfing C, Bögemann M, Goebell PJ, Hammerer P, Machtens S, Pfister D, Schwentner C, Steuber T, von Amsberg G, Schostak M.
    Urologe A; 2019 Sep; 58(9):1066-1072. PubMed ID: 31041460
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Modern treatment of metastatic hormone-sensitive prostate cancer].
    Küronya Z, Bíró K, Géczi L, Maráz A.
    Orv Hetil; 2018 Oct; 159(41):1664-1671. PubMed ID: 30295043
    [Abstract] [Full Text] [Related]

  • 12. Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy.
    Barata P, Emamekhoo H, Mendiratta P, Koshkin V, Tyler A, Ornstein M, Rini BI, Gilligan T, Kyriakopoulos C, Garcia JA.
    Prostate; 2018 Sep; 78(13):1035-1041. PubMed ID: 29882332
    [Abstract] [Full Text] [Related]

  • 13. Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review.
    Loblaw DA, Walker-Dilks C, Winquist E, Hotte SJ, Genitourinary Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care.
    Clin Oncol (R Coll Radiol); 2013 Jul; 25(7):406-30. PubMed ID: 23587782
    [Abstract] [Full Text] [Related]

  • 14. Safety of antiandrogen therapy for treating prostate cancer.
    Ricci F, Buzzatti G, Rubagotti A, Boccardo F.
    Expert Opin Drug Saf; 2014 Nov; 13(11):1483-99. PubMed ID: 25270521
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. New Antiandrogen Compounds Compared to Docetaxel for Metastatic Hormone Sensitive Prostate Cancer: Results from a Network Meta-Analysis.
    Marchioni M, Di Nicola M, Primiceri G, Novara G, Castellan P, Paul AK, Veccia A, Autorino R, Cindolo L, Schips L.
    J Urol; 2020 Apr; 203(4):751-759. PubMed ID: 31689158
    [Abstract] [Full Text] [Related]

  • 17. Androgen deprivation therapy with chemotherapy or abiraterone for patients with metastatic hormone-naive prostate cancer: a systematic review and meta-analysis.
    Sun G, Chen X, Gong U, Chen Y, Li G, Wei F, Jiang A, Niu Y, Shang Z.
    Future Oncol; 2019 Apr; 15(10):1167-1179. PubMed ID: 30741558
    [Abstract] [Full Text] [Related]

  • 18. Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer.
    Shiota M, Eto M.
    Int J Urol; 2016 May; 23(5):360-9. PubMed ID: 27062039
    [Abstract] [Full Text] [Related]

  • 19. Androgen Deprivation Therapy and Secondary Hormone Therapy in the Management of Hormone-sensitive and Castration-resistant Prostate Cancer.
    Saad F, Fizazi K.
    Urology; 2015 Nov; 86(5):852-61. PubMed ID: 26282624
    [Abstract] [Full Text] [Related]

  • 20. Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.
    Bellmunt J, Kheoh T, Yu MK, Smith MR, Small EJ, Mulders PF, Fizazi K, Rathkopf DE, Saad F, Scher HI, Taplin ME, Davis ID, Schrijvers D, Protheroe A, Molina A, De Porre P, Griffin TW, de Bono JS, Ryan CJ, Oudard S.
    Eur Urol; 2016 May; 69(5):924-32. PubMed ID: 26508309
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.